We perform functional genome annotation on an unprecedented scale using our unique SuRE technology. Our screening services enable the identification of regulatory DNA elements as well as the mutations in these elements that define traits and diseases in humans, plants and animals. The SuRE method is in essence a strategy to analyze millions of DNA elements for their activity as promoters or enhancers in a single experiment. By analyzing ~300 million DNA elements of ~300bp length, an entire human genome can be analyzed exhaustively at an approximate 30 fold coverage.
The only required input is DNA and once a SuRE library is established it can analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant (e.g. stimulatory) conditions. For further reading please see this publication: https://rdcu.be/bH2xl.

Recently we (through Gen-X BV) closed an exclusive deal with uniQure for the gene therapy field underpinning the interest and added value of our platform. With the newly incorporated spin out company Annogen we commercialize our proprietary technology outside the gene therapy field focusing on cell therapy and other applications.

A short overview:

SuRE™ technology – Functional Annotation of the Non-coding Genome:

Identification of
1. regulatory DNA elements
2. mutations in these elements that define traits and diseases in humans, plants and animals.

Applied for
1. cell therapy (cell and tissue specific inducible regulatory elements)
2. drug discovery (>95% of disease-protective and –causative variants lie in regulatory DNA)
3. patient-drug response (identifying non-coding variants to predict differential drug responses)